Stoke Therapeutics, Inc.STOKEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Revenue
$-2.5M
Gross Profit
N/A
Operating Profit
$-33.3M
Net Profit
$-30.7M
Gross Margin
N/A
Operating Margin
1340.7%
Net Margin
1235.6%
YoY Growth
-176.8%
EPS
$-0.69
Stoke Therapeutics, Inc. Q2 FY2023 Financial Summary
Stoke Therapeutics, Inc. reported revenue of $-2.5M (down 176.8% YoY) for Q2 FY2023, with a net profit of $-30.7M (down 24.3% YoY) (1235.6% margin).
Key Financial Metrics
| Total Revenue | $-2.5M |
|---|---|
| Net Profit | $-30.7M |
| Gross Margin | N/A |
| Operating Margin | 1340.7% |
| Report Period | Q2 FY2023 |
Stoke Therapeutics, Inc. Quarterly Revenue & Net Profit History
Stoke Therapeutics, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $158.6M | +3661.1% | $112.9M | 71.2% |
| Q4 FY2024 | $22.6M | +707.4% | $-10.5M | -46.4% |
| Q2 FY2023 | $-2.5M | -176.8% | $-30.7M | 1235.6% |
Income Statement
| Q2 2023 | Q4 2024 | Q1 2025 | |
|---|---|---|---|
| Revenue | $-2.5M | $22.6M | $158.6M |
| YoY Growth | -176.8% | 707.4% | 3661.1% |
Balance Sheet
| Q2 2023 | Q4 2024 | Q1 2025 | |
|---|---|---|---|
| Assets | $256.9M | $271.6M | $406.9M |
| Liabilities | $66.7M | $42.5M | $56.8M |
| Equity | $190.2M | $229.0M | $350.1M |
Cash Flow
| Q2 2023 | Q4 2024 | Q1 2025 | |
|---|---|---|---|
| Operating CF | $-21.8M | $-23.2M | $131.8M |